Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Net Cash Flow (2019 - 2025)

Bioadaptives' Net Cash Flow history spans 7 years, with the latest figure at -$151309.0 for Q3 2025.

  • For Q3 2025, Net Cash Flow fell 446.58% year-over-year to -$151309.0; the TTM value through Sep 2025 reached -$266620.0, down 90.07%, while the annual FY2024 figure was $76694.0, 116.83% up from the prior year.
  • Net Cash Flow for Q3 2025 was -$151309.0 at Bioadaptives, down from -$110982.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $111951.0 in Q3 2023 and bottomed at -$151309.0 in Q3 2025.
  • The 5-year median for Net Cash Flow is -$11339.0 (2022), against an average of -$13653.2.
  • The largest annual shift saw Net Cash Flow surged 3057.68% in 2021 before it crashed 1654.5% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $16597.0 in 2021, then crashed by 64.61% to $5873.0 in 2022, then plummeted by 1654.5% to -$91296.0 in 2023, then skyrocketed by 202.5% to $93577.0 in 2024, then plummeted by 261.69% to -$151309.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Net Cash Flow are -$151309.0 (Q3 2025), -$110982.0 (Q2 2025), and -$97906.0 (Q1 2025).